Data / Form D filings / Oisin Biotechnologies, Inc.
Oisin Biotechnologies, Inc.: Form D filings
Oisin Biotechnologies, Inc., a biotechnology company in Seattle, WA, filed 5 Form D notices with the SEC between 2020 and 2024. The latest, on July 12, 2024, reports $5.4 million sold of a $17.9 million offering to 36 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 800 5TH AVENUE, SUITE 4100, Seattle, WA, 98104
- Phone
- (206) 880-1166
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1801885
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jul 12, 2024 | New notice | $17,879,999 | $5,380,000 | $12,499,999 | 36 | Jun 28, 2024 | sec.gov |
| Aug 6, 2021 | New notice | $5,000,000 | $475,000 | $4,525,000 | 8 | Jul 24, 2021 | sec.gov |
| May 28, 2021 | Amendment | $9,531,422 | $9,531,365 | $57 | 90 | Jun 10, 2020 | sec.gov |
| Jun 23, 2020 | New notice | $5,000,000 | $2,118,936 | $2,881,064 | 27 | Jun 10, 2020 | sec.gov |
| Feb 25, 2020 | New notice | $3,000,000 | $2,974,976 | $25,024 | 48 | Dec 19, 2017 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Eric Garcia | Executive Officer | |
| Matthew Scholz | Executive Officer, Director | |
| David Gobel | Director | |
| Stephen Hilbert | Executive Officer | |
| John Lewis | Executive Officer | |
| Gary Hudson | Executive Officer, Director | |
| Danjuma Quarless | Director |
Other biotechnology companies in Washington that filed recently
- Key Proteo, Inc. $2.3 million · Oct 23, 2026
- Inmedix, Inc. $4 million · Oct 22, 2026
- Q-Immune, Inc. $25,000 · Sep 28, 2026
- Hexamer Therapeutics, Inc $500,000 · Sep 15, 2026
- MalarVx, Inc. $125,000 · Aug 25, 2026
- Strella Biotechnology, Inc. $1.8 million · Aug 14, 2026
Every Form D from the week of Jul 8, 2024 · All recent filings in Washington · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Oisin Biotechnologies, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.